EcoDrugPlus

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSG00000277791
Gene: PSMB3
Gene Synonyms: HC10-II,MGC4147
6 APIs:
150 Enzyme and pathways 7 Cross references
240 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSG00000159377
Gene: PSMB4
Gene Synonyms: HN3,PROS26
6 APIs:
150 Enzyme and pathways 8 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSG00000100804
Gene: PSMB5
Gene Synonyms: MB1
6 APIs:
150 Enzyme and pathways 7 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSG00000142507
Gene: PSMB6
Gene Synonyms: DELTA,Y
6 APIs:
150 Enzyme and pathways 7 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSG00000136930
Gene: PSMB7
Gene Synonyms: Z
6 APIs:
151 Enzyme and pathways 7 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSG00000204264
Gene: PSMB8
Gene Synonyms: BETA5I,D6S216E,LMP7,PSMB5I,RING10
6 APIs:
152 Enzyme and pathways 9 Cross references
221 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSG00000240065
Gene: PSMB9
Gene Synonyms: BETA1I,LMP2,PSMB6I,RING12
6 APIs:
150 Enzyme and pathways 8 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSG00000175166
Gene: PSMD2
Gene Synonyms: MGC14274,P97,RPN1,S2,TRAP2
5 APIs:
151 Enzyme and pathways 7 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSG00000100764
Gene: PSMC1
Gene Synonyms: P56,RPT2,S4
5 APIs:
152 Enzyme and pathways 8 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSG00000161057
Gene: PSMC2
Gene Synonyms: MSS1,NBLA10058,RPT1,S7
5 APIs:
151 Enzyme and pathways 7 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSG00000165916
Gene: PSMC3
Gene Synonyms: RPT5,TBP-1,TBP1
5 APIs:
151 Enzyme and pathways 8 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSG00000013275
Gene: PSMC4
Gene Synonyms: MGC13687,MGC23214,MGC8570,MIP224,RPT3,S6,TBP-7,TBP7
5 APIs:
150 Enzyme and pathways 7 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).